Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

2.

CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma.

Dakappagari N, Ho SN, Gascoyne RD, Ranuio J, Weng AP, Tangri S.

Cytometry B Clin Cytom. 2012 Mar;82(2):112-9. doi: 10.1002/cyto.b.20631. Epub 2011 Nov 10.

3.

Cannabis use amongst patients with inflammatory bowel disease.

Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H.

Eur J Gastroenterol Hepatol. 2011 Oct;23(10):891-6. doi: 10.1097/MEG.0b013e328349bb4c.

PMID:
21795981
4.

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S.

Blood. 2010 Jan 21;115(3):489-95. doi: 10.1182/blood-2009-08-237727. Epub 2009 Oct 20.

5.

An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.

Dakappagari N, Neely L, Tangri S, Lundgren K, Hipolito L, Estrellado A, Burrows F, Zhang H.

Biomarkers. 2010 Feb;15(1):31-8. doi: 10.3109/13547500903261347.

PMID:
19747088
6.

Rationally engineered therapeutic proteins with reduced immunogenicity.

Tangri S, Mothé BR, Eisenbraun J, Sidney J, Southwood S, Briggs K, Zinckgraf J, Bilsel P, Newman M, Chesnut R, Licalsi C, Sette A.

J Immunol. 2005 Mar 15;174(6):3187-96.

7.

Rationally engineered proteins or antibodies with absent or reduced immunogenicity.

Tangri S, LiCalsi C, Sidney J, Sette A.

Curr Med Chem. 2002 Dec;9(24):2191-9. Review.

PMID:
12470241
8.

Optimizing vaccine design for cellular processing, MHC binding and TCR recognition.

Sette A, Newman M, Livingston B, McKinney D, Sidney J, Ishioka G, Tangri S, Alexander J, Fikes J, Chesnut R.

Tissue Antigens. 2002 Jun;59(6):443-51. Review.

PMID:
12445314
9.

Epitope identification and vaccine design for cancer immunotherapy.

Sette A, Keogh E, Ishioka G, Sidney J, Tangri S, Livingston B, McKinney D, Newman M, Chesnut R, Fikes J.

Curr Opin Investig Drugs. 2002 Jan;3(1):132-9. Review.

PMID:
12054064
10.
11.

Presentation of peptide antigens by mouse CD1 requires endosomal localization and protein antigen processing.

Tangri S, Brossay L, Burdin N, Lee DJ, Corr M, Kronenberg M.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14314-9.

12.

Antigen-presenting function of mouse CD1: one molecule with two different kinds of antigenic ligands.

Brossay L, Burdin N, Tangri S, Kronenberg M.

Immunol Rev. 1998 Jun;163:139-50. Review.

PMID:
9700507
13.

Mouse CD1-autoreactive T cells have diverse patterns of reactivity to CD1+ targets.

Brossay L, Tangri S, Bix M, Cardell S, Locksley R, Kronenberg M.

J Immunol. 1998 Apr 15;160(8):3681-8.

14.

Immunodystrophism, T cells, cytokines, and pregnancy failure.

Raghupathy R, Tangri S.

Am J Reprod Immunol. 1996 Apr;35(4):291-6. Review. No abstract available.

PMID:
8739444
15.

Antigen-presenting function of the mouse CD1 molecule.

Tangri S, Holcombe HR, Castaño AR, Miller JE, Teitell M, Huse WE, Peterson PA, Kronenberg M.

Ann N Y Acad Sci. 1996 Feb 13;778:288-96. Review.

PMID:
8610982
16.

Antigen-presenting function of the TL antigen and mouse CD1 molecules.

Cheroutre H, Holcombe HR, Tangri S, Castaño AR, Teitell M, Miller JE, Cardell S, Benoist C, Mathis D, Huse WD, et al.

Immunol Rev. 1995 Oct;147:31-52. Review.

PMID:
8847078
17.

CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice.

Cardell S, Tangri S, Chan S, Kronenberg M, Benoist C, Mathis D.

J Exp Med. 1995 Oct 1;182(4):993-1004.

18.

Peptide binding and presentation by mouse CD1.

Castaño AR, Tangri S, Miller JE, Holcombe HR, Jackson MR, Huse WD, Kronenberg M, Peterson PA.

Science. 1995 Jul 14;269(5221):223-6.

PMID:
7542403
19.

Maternal anti-placental reactivity in natural, immunologically-mediated fetal resorptions.

Tangri S, Wegmann TG, Lin H, Raghupathy R.

J Immunol. 1994 May 15;152(10):4903-11.

PMID:
8176211
20.
21.

Ethical issues in the new reproductive technologies: perspectives from feminism and the psychology profession.

Tangri SS, Kahn JR.

Prof Psychol Res Pr. 1993 Aug;24(3):271-80. No abstract available.

PMID:
11652331
22.

Recombinant fusion protein identified by lepromatous sera mimics native Mycobacterium leprae in T-cell responses across the leprosy spectrum.

Laal S, Sharma YD, Prasad HK, Murtaza A, Singh S, Tangri S, Misra RS, Nath I.

Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):1054-8.

23.

Human immune response to recombinant interferon gamma and protein antigen LSR2.

Nath I, Laal S, Sivasai KS, Tangri S, Murtaza A, Singh S, Wilfred D, Misra RS.

Trop Med Parasitol. 1990 Sep;41(3):324-5. No abstract available.

PMID:
1701565
24.

The breathing pattern in chronic obstructive lung disease during the performance of some common daily activities.

Tangri S, Woolf CR.

Chest. 1973 Jan;63(1):126-7. No abstract available.

PMID:
4684100
25.

A note on self-concept as an insulator against delinquency.

Schwartz M, Tangri SS.

Am Sociol Rev. 1965 Dec;30(6):922-6. No abstract available.

PMID:
5846311

Supplemental Content

Loading ...
Support Center